Optimizing outcomes and treatment sequences in EGFR mutation-positive non-small-cell lung cancer: recent updates

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• Several epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are available for EGFR mutation-positive non-small cell lung cancer (NSCLC).
• The optimal sequencing of these therapies, particularly the third-generation TKI osimertinib, remains a critical clinical question.
• No standard targeted treatments exist post-progression on first- or second-generation TKIs.

Purpose of the Study:

• To review clinical studies assessing the efficacy of sequential EGFR TKI regimens.
• To evaluate the role of osimertinib in different treatment sequences for EGFR mutation-positive NSCLC.
• To determine the viability of sequential EGFR TKI use in real-world clinical practice.

Main Methods:

• Review of recent clinical studies on sequential EGFR TKI treatment strategies.
• Analysis of treatment outcomes in patients with EGFR mutation-positive NSCLC.
• Evaluation of osimertinib's efficacy in various treatment lines.

Main Results:

• Sequential EGFR TKI regimens have demonstrated activity in clinical studies.
• The use of osimertinib, especially in later lines of therapy after resistance mutations emerge, is supported by evidence.
• Real-world data suggest sequential EGFR TKI use is a practical treatment approach.

Conclusions:

• Sequential administration of EGFR TKIs is a feasible and effective strategy for managing EGFR mutation-positive NSCLC.
• The findings support considering sequential EGFR TKI use as a standard approach in clinical practice.
• Further research may refine optimal sequencing protocols for improved patient outcomes.